Sign in Subscribe
Artificial intelligence

Artificial Intelligence in Pharmaceutical Market to Reach USD 13.46 Billion by 2032

Strategic Insights

— 1 min read

The global artificial intelligence (AI) in pharmaceutical market is rapidly growing, driven by the increasing demand for rapid drug discovery, precision medicine, and efficient clinical trials. The market is projected to reach USD 13.46 billion by 2032, expanding at a CAGR of 29.33 percent during the forecast period of 2025-2032. The U.S. will account for the largest share of the AI in pharmaceutical market within North America, driven by the presence of a well-established pharmaceutical and technology ecosystem, excellent R&D infrastructure, and high adoption of AI across drug discovery and clinical development.

Key Takeaways:

  • The global AI in pharmaceutical market was valued at USD 1.73 billion in 2024 and is expected to reach USD 13.46 billion by 2032.
  • The U.S. AI in pharmaceutical market was estimated at USD 0.47 billion in 2024 and is expected to reach USD 3.67 billion by 2032.
  • The drug discovery segment dominated the AI in pharmaceutical market with a 64.29 percent market share in 2024, leveraging AI algorithms to analyze substantial datasets and determine possible favorable candidate molecules.
  • Machine learning is the leading technology segment in the AI in pharmaceutical market, with a 48.24 percent market share in 2024, attributed to its unmatched capability in analyzing complex biomedical data.
  • The software segment holds the maximum share in the AI in pharmaceutical market, with a 55.10 percent market share in 2024, providing software tools for data processing, predictive modeling, and algorithm development for drug discovery, diagnostics, and clinical trials.
  • North America is the leading region for the AI in pharmaceutical market, with a 36.16 percent market share in 2024, while Asia Pacific is expected to grow at the highest CAGR of 30.12 percent during the forecast period.

Statistics:

  • CAGR: 29.33 percent (2025-2032)
  • Market value: USD 1.73 billion (2024), USD 13.46 billion (2032)
  • U.S. market value: USD 0.47 billion (2024), USD 3.67 billion (2032)
  • Drug discovery segment market share: 64.29 percent (2024)
  • Machine learning market share: 48.24 percent (2024)
  • Software segment market share: 55.10 percent (2024)
  • North America market share: 36.16 percent (2024)
  • Asia Pacific CAGR: 30.12 percent (2025-2032)

Sources:

  • SNS Insider
  • IBM Watson Health
  • Google DeepMind
  • Isomorphic Labs
  • Microsoft Corp.
  • Nvidia Corp.
  • Insilico Medicine
  • Exscientia
  • Recursion Pharmaceuticals
  • BenevolentAI
  • BioXcel Therapeutics
  • PathAI

Read more